NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the closing of its previously announced acquisition of the exclusive U.S. commercial rights to five branded ophthalmic products: ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®.
Amid a major restructuring and the spinoff of generics unit Sandoz, Novartis isn't done shaking things up.
Imprimis NJOF, LLC Receives FDA Warning Letter
AUSTIN, Texas--(BUSINESS WIRE)--Mati Therapeutics Inc. (“Mati”) announced that it has completed a Phase II clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s proprietary Evolute® sustained ocular punctal plug drug delivery platform. The trial was a multi-center, randomized, masked evaluation of Nepafenac Evolute® vs. placebo in 56 patients undergoing cataract surgery. The primary endpoint was pain with a secondary endpoint of inflammation following surgery.
AUSTIN, Texas--(BUSINESS WIRE)--Mati Therapeutics Inc. (“Mati”) announced that it has completed a planned interim analysis of an ongoing Phase II clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s proprietary Evolute® sustained ocular drug delivery platform.
Over time, the approved therapeutic uses of prescription medicines registered on the Australian Register of Therapeutic Goods (ARTG) can change.
Imprimis Pharmaceuticals Receives FDA Warning Letter
Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, today announced plans to launch its IV Free™ MKO Melt™ conscious sedation formulations and new triple combination eye drop that includes nepafenac at the American Society of Cataract and Refractive Surgery (ASCRS) Congress in New Orleans, Louisiana, May 6 - 10, 2016.